Drawing for IGEM

USPTO serial 88337703

IGEM

Reviewed by CopyMark Law Group

Status 601
Filing date
Status date
Registration date
—
Examiner
CHISOLM, KEVON
Law office
TMEG LAW OFFICE 103 - EXAMINING ATTORNEY ASSIGNED

What this means

This page summarizes the public USPTO record for this serial number, including owners, goods and services, and prosecution history.

Need help with IGEM?

If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.

Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.

Owner

Attorney of record

The USPTO lists this attorney as the applicant's representative for correspondence on this application.

Susan Piascik Christoff

Susan Piascik Christoff COOLEY LLP1299 PENNSYLVANIA AVE., N.W.SUITE 700WASHINGTON, DC 20004

Goods and services

ClassDescriptionStatusFirst use
042Scientific and technological services and research and design relating thereto; industrial analysis and research services; pharmaceutical drug development services; pharmaceutical research and development; scientific laboratory services; medical research laboratory services; laboratory research services relating to pharmaceuticals; clinical research; clinical trials; conducting clinical trials for pharmaceutical products; providing information about the results of clinical trials for pharmaceutical products; scientific research for medical purposes in the area of cancerous diseases; research and development services in the fields of oncology, immunology and immuno-oncologyACTIVE—
044Medical services; medical treatment services; medical screening; medical monitoring, testing, inspection and analysis services; medical services relating to the diagnosis and treatment of cancerous diseases; pharmaceutical services; pharmaceutical advisory services; laboratory analysis services relating to the treatment of persons; laboratory analysis services relating to the diagnosis and treatment of cancerous diseases; providing cancer screening services; medical analysis services for cancer diagnosis and prognosis; RNA or DNA analysis for cancer diagnosis and prognosis; medical services in the field of oncology, immunology and immuno-oncology; providing advice relating to oncology, immunology and immuno-oncology; providing on-line information relating to oncology, immunology and immuno-oncologyACTIVE—

Related trademarks

CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.

Prosecution history

DateCodeEventWhat it means
Nov 5, 2020MAB1ABANDONMENT NOTICE E-MAILED - EXPRESS ABANDONMENT—
Nov 5, 2020ABN1ABANDONMENT - EXPRESS MAILED—
Nov 4, 2020EXARTEAS EXPRESS ABANDONMENT RECEIVED—
Nov 3, 2020CHANAPPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED—
Nov 3, 2020TCCATEAS CHANGE OF CORRESPONDENCE RECEIVED—
Nov 3, 2020COARTEAS CHANGE OF OWNER ADDRESS RECEIVED—
Sep 3, 2020GNS2NOTIFICATION OF INQUIRY AS TO SUSPENSION E-MAILED—
Sep 3, 2020GNSIINQUIRY TO SUSPENSION E-MAILED—
Sep 3, 2020CNSISUSPENSION INQUIRY WRITTEN—
Aug 26, 2020RCCKSUSPENSION CHECKED - TO ATTORNEY FOR ACTION—
Aug 19, 2020ALIEASSIGNED TO LIE—
Jan 21, 2020GNS3NOTIFICATION OF LETTER OF SUSPENSION E-MAILED—
Jan 21, 2020GNSLLETTER OF SUSPENSION E-MAILED—
Jan 21, 2020CNSLSUSPENSION LETTER WRITTEN—
Jan 2, 2020TEMETEAS/EMAIL CORRESPONDENCE ENTERED—
Jan 2, 2020CRFACORRESPONDENCE RECEIVED IN LAW OFFICE—
Jan 2, 2020ERSITEAS RESPONSE TO SUSPENSION INQUIRY RECEIVED—
Dec 16, 2019GNS2NOTIFICATION OF INQUIRY AS TO SUSPENSION E-MAILED—
Dec 16, 2019GNSIINQUIRY TO SUSPENSION E-MAILED—
Dec 16, 2019CNSISUSPENSION INQUIRY WRITTEN—
May 22, 2019GNS3NOTIFICATION OF LETTER OF SUSPENSION E-MAILED—
May 22, 2019GNSLLETTER OF SUSPENSION E-MAILED—
May 22, 2019CNSLSUSPENSION LETTER WRITTEN—
May 22, 2019DOCKASSIGNED TO EXAMINER—
Apr 1, 2019NWOSNEW APPLICATION OFFICE SUPPLIED DATA ENTERED—
Mar 16, 2019NWAPNEW APPLICATION ENTERED—

Frequently asked questions

Related guidance